Reuters -- Bayer has started enrolling participants for the last stage of testing of its Alzheimer’s marker florbetaben, which could offer a way to diagnose early onset of the disease, the drugmaker said on Monday.
Reuters -- Bayer has started enrolling participants for the last stage of testing of its Alzheimer’s marker florbetaben, which could offer a way to diagnose early onset of the disease, the drugmaker said on Monday.
